Bain Capital-backed Emcure Pharmaceuticals has filed preliminary papers with capital markets regulator Sebi to raise funds through an initial share sale.

The initial public offering (IPO) comprises fresh issuance of equity shares worth Rs 1,100 crore and an offer of sale of 18,168,356 shares by promoters and existing shareholders, according to the draft red herring prospectus (DRHP).…

Emcure Pharmaceuticals Limited, one of the leading Indian pharmaceutical companies engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products across several major therapeutic areas, has filed its Draft Red Hearing Prospectus (DRHP) with market regulator Securities and Exchange Board of India (SEBI) to raise funds via initial public offering (IPO).…

Emcure Pharmaceuticals Limited is a Non-govt company, incorporated on 16 Apr, 1981. It's a public unlisted company and is classified as'company limited by shares'.

Company's authorized capital stands at Rs 20000.0 lakhs and has 90.42606% paid-up capital which is Rs 18085.21 lakhs. Emcure Pharmaceuticals Limited last annual general meet (AGM) happened on 08 Aug, 2017. The company last updated its financials on 31 Mar, 2017 as per Ministry of Corporate Affairs (MCA).…

Emcure Pharmaceuticals is an Indian multinational pharmaceutical company headquartered in Pune, Maharashtra. Emcure's product portfolio includes tablets, capsules (both Softgel capsules and hard-gel capsules) and injectables.

Emcure is planning to raise money through an initial public offering for some time now.
https://en.wikipedia.org/wiki/Emcure_Pharmaceuticals

Speaking at the 76th session of the UN General Assembly last month, Prime Minister Narendra Modi said: “India has developed the world’s first DNA vaccine.

An m-RNA vaccine is in the final stages of development.” The announcement in the lofty halls of the UNGA in New York refers to a 15-year-old Pune-based pharmaceutical company, Gennova Biopharmaceuticals, the biotech subsidiary of the Rs 6,056-crore Emcure Group, which is developing the country’s first indigenous mRNA Covid-19…

Founded in 1983, Emcure Pharmaceuticals manufactures and globally markets a wide variety of pharmaceutical products. It has filed its draft red herring prospectus (DRHP) with the Securities Exchange Board of India (SEBI) to raise funds through an IPO (initial public offering). The company is aiming to raise ₹4,000 crore through this IPO.

The Pune-based company is the 12th largest pharmaceutical company in India. As per the CRISIL report FY21, Emcure Pharmaceutical Limited is a leader…

Pune-based Emcure Pharmaceuticals, one of India’s biggest unlisted pharma companies, filed its draft red herring prospectus (DRHP) with the market regulator Sebi on Thursday to raise money through an initial public offer.

The issue estimated to be around Rs 4,500 crore would comprise fresh shares of up to Rs 1,100 crore and an offer for sale by promoters and an existing investor of up to 18.17 million shares.

Read more at…

India’s first mRNA-based Covid-19 vaccine, from Gennova Biopharma, a subsidiary of Pune-based Emcure Pharmaceuticals, is in its final stages. Soumya Swaminathan, chief scientist at the World Health Organization (WHO), visited Gennova’s vaccine manufacturing facility at Hinjewadi in Pune on Monday. The company is awaiting regulatory approvals for its mRNA vaccine for Covid-19.…

The Central Drugs Standard Control Organisation (CDSCO), India's National Regulatory Authority, has approved Gennova Biopharmaceuticals Limited's work on the country's first mRNA-based COVID-19 vaccine for its clinical data of the phase-1 study.

"Vaccine Subject Expert Committee (SEC) reviewed the interim phase-1 data and found that HGCO19 was safe, tolerable, and immunogenic in the participants of the study. The Director General (I), CDSCO, approved the proposal submitted for the phase…

Clinical trials of the two Indian vaccine candidates—the mRNA jab from Gennova and the Receptor Binding Protein (RBD) vaccine by Biological E—are expected to speed up after the government agreed to supply doses of Covishield vaccines to these companies for a comparator study, people aware of the development said.

Both companies had been stuck with their vaccine development as they were unable to get doses from Serum Institute of India’s Covishield and Bharat Biotech’s Covaxin to…

Gennova Biopharmaceuticals’ Covid-19 jab HGCO19, based on the mRNA technology platform, will be a lyophilized vaccine or one that is based on freeze-drying. This should help store the vaccine at much higher temperatures than the stringent sub-zero temperatures required to maintain a stable cold chain for other mRNA vaccines globally.

The lyophilized vaccine will come in a powder form and it will be mixed with diluents before administration.…

HDT Bio Corp., a developer of immunotherapies for oncology and infectious diseases, announced today that its development partner in India, Gennova Biopharmaceuticals, successfully completed a Phase 1 trial of its COVID-19 RNA vaccine candidate HGCO19 and Indian regulatory authorities have approved the start of pivotal Phase 2/3 trials. This vaccine uses HDT Bio’s proprietary LIONTM RNA-delivery technology.…

HDT Bio Corp., a developer of immunotherapies for oncology and infectious diseases, announced today that its development partner in India, Gennova Biopharmaceuticals, successfully completed a Phase 1 trial of its COVID-19 RNA vaccine candidate HGCO19 and Indian regulatory authorities have approved the start of pivotal Phase 2/3 trials. This vaccine uses HDT Bio’s proprietary LIONTM RNA-delivery technology.…

Pune-based Gennova Biopharmaceuticals, a subsidiary of Emcure Pharma, is set to soon start phase-2 and 3 trials of India’s first mRNA based vaccine for Covid-19. “They have got regulatory approvals and the last-stage trials are expected to start soon. The company will soon start enrolment for the trials,” said a senior government official.

The study will be conducted at 10-15 sites in phase-2 and 22-27 sites in phase-3. To assess the immunogenicity of the mRNA vaccine, Gennova will…

A Tis Hazari court on Friday summoned managing director of real estate major Emaar MGF Shravan Gupta as an accused after taking cognisance of the Income Tax department's complaint against him for allegedly not furnishing details of his foreign bank accounts. Additional Chief Metropolitan Magistrate Devendra Kumar Sharma has summoned Gupta on March 24. Gupta's name, along with others, has allegedly cropped up in the black money case. The Income Tax Department, in its complaint against Gupta,…

The Drug Controller General of India has approved the Phase 2 and 3 clinical trials of India's first Covid-19 mRNA vaccine.

Pune-based pharma major Gennova Biopharmaceuticals Ltd is developing the nation's first mRNA-based Covid-19 vaccine. It is among a few pharmaceutical firms worldwide, including Moderna Inc and Pfizer Inc, to use mRNA technology in its coronavirus shot. These vaccines do not use a live virus to generate an immune response but prompt the human body to make a…

For the first time, since the massive vaccination drive began, India administered more than one crore vaccine doses in a single day against Covid-19. This is the highest-ever vaccination achieved in a single day since the start of the vaccination drive in January.

In another significant achievement, India's Covid-19 vaccination coverage has crossed the 62 crore landmark and presently stands at 62,17,06,882, as per the provisional report of the Health Ministry.…

The Drug Controller General of India has approved the Phase 2 and 3 clinical trials of India's first Covid-19 mRNA vaccine.

Pune-based pharma major Gennova Biopharmaceuticals Ltd is developing the nation's first mRNA-based Covid-19 vaccine.

It is among a few pharmaceutical firms worldwide, including Moderna Inc and Pfizer Inc, to use mRNA technology in its coronavirus shot.…

The Gennova Biopharmaceuticals Ltd. is a Pune-based biotechnology company that has developed the vaccine. The interim clinical data of the Phase I trial of the vaccine was submitted for review to the Central Drugs Standard Control Organisation (CDSCO).

Dr. Sanjay Singh, CEO of Gennova Biopharmaceuticals Ltd said, “After establishing the safety of our mRNA-based COVID-19 vaccine candidate HGCO19 in Phase I clinical trial, Gennova’s focus is to start Phase II/III pivotal clinical trial.…

The Drug Controller General of India has approved the Phase 2 and 3 clinical trials of India’s first Covid-19 mRNA vaccine.

Pune-based pharma major Gennova Biopharmaceuticals Ltd is developing the nation’s first mRNA-based Covid-19 vaccine. It is among a few pharmaceutical firms worldwide, including Moderna Inc and Pfizer Inc, to use mRNA technology in its coronavirus shot. These vaccines do not use a live virus to generate an immune response but prompt the human body to make a…